Gilead discontinues cicletanine for PAH

Gilead Sciences Inc. (NASDAQ:GILD) discontinued development of cicletanine to treat pulmonary arterial hypertension after the diuretic missed the primary endpoint of improving 6-minute walk distance (6MWD) at 12 weeks vs. placebo in a Phase II trial. Patients received placebo or oral cicletanine with or without stable background PAH therapy. Gilead said data will be presented at the European Respiratory Society meeting in Vienna in September. The company declined to provide details regarding future development of cicletanine in other indications. ...